Arcutis Biotherapeutics Inc (NASDAQ: ARQT) is 45.29% higher on its value in year-to-date trading and has touched a low of $7.86 and a high of $17.75 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ARQT stock was last observed hovering at around $15.4 in the last trading session, with the day’s gains setting it 0.03%.
Currently trading at $15.43, the stock is 7.97% and 10.08% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.77 million and changing 0.19% at the moment leaves the stock 18.55% off its SMA200. ARQT registered 10.77% gain for a year compared to 6-month loss of 13.21%. The firm has a 50-day simple moving average (SMA 50) of $13.9989 and a 200-day simple moving average (SMA200) of $12.955575.
The stock witnessed a 14.89% gain in the last 1 month and extending the period to 3 months gives it a 19.24%, and is 8.51% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.19% over the week and 4.95% over the month.
Arcutis Biotherapeutics Inc (ARQT) has around 342 employees, a market worth around $1.84B and $212.82M in sales. Fwd P/E is 99.64. Profit margin for the company is -60.95%. Distance from 52-week low is 96.31% and -13.07% from its 52-week high. The company has generated returns on investments over the last 12 months (-51.35%).
The EPS is expected to grow by 52.80% this year
325.0 institutions hold shares in Arcutis Biotherapeutics Inc (ARQT), with institutional investors hold 111.09% of the company’s shares. The shares outstanding are 119.14M, and float is at 104.81M with Short Float at 19.65%. Institutions hold 108.90% of the Float.
The top institutional shareholder in the company is JENNISON ASSOCIATES LLC with over 11.57 million shares valued at $107.62 million. The investor’s holdings represent 9.3712 of the ARQT Shares outstanding. As of 2024-06-30, the second largest holder is SUVRETTA CAPITAL MANAGEMENT, LLC with 10.0 million shares valued at $93.04 million to account for 8.1021 of the shares outstanding. The other top investors are RUBRIC CAPITAL MANAGEMENT LP which holds 9.82 million shares representing 7.95 and valued at over $91.3 million, while FRAZIER LIFE SCIENCES MANAGEMENT, L.P. holds 7.1147 of the shares totaling 8.79 million with a market value of $81.7 million.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
The most recent transaction is an insider sale by Burnett Patrick,. SEC filings show that Burnett Patrick sold 23,000 shares of the company’s common stock on Jul 10 ’25 at a price of $15.05 per share for a total of $0.35 million. Following the sale, the insider now owns 0.12 million shares.
Arcutis Biotherapeutics Inc disclosed in a document filed with the SEC on Jul 14 ’25 that Burnett Patrick sold a total of 5,750 shares of the company’s common stock. The trade occurred on Jul 14 ’25 and was made at $15.07 per share for $86654.0. Following the transaction, the insider now directly holds 0.12 million shares of the ARQT stock.
